Effects of ACE inhibitors or β-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American heart failure trial

Jalal K. Ghali, S. William Tam, Keith C. Ferdinand, Jo Ann Lindenfeld, Michael L. Sabolinski, Anne L. Taylor, Manuel Worcel, Charles L. Curry, Jay N. Cohn

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: In the A-HeFT (African-American Heart Failure Trial), treatment of African-American patients with New York Heart Association (NYHA) class III/IV heart failure (HF) with fixed-dose combination (FDC) of isosorbide dinitrate/hydralazine (I/H) reduced mortality and morbidity and improved patient reported functional status compared with standard therapy alone. Objective: To examine the benefit of FDC I/H in subgroups based on baseline drug therapy and to investigate whether ACE inhibitors and/or angiotensin receptor antagonists (angiotensin receptor blockers) [ARBs] or β-adrenoceptor antagonists (β-blockers) provided additional benefit in FDC I/H-treated African-American patients with HF. Study design: The A-HeFT was a double-blind, placebo-controlled study enrolling 1050 patients stabilized on optimal HF therapies and with NYHA class III/IV HF with systolic dysfunction conducted during the years 2001-4 with up to 18 months follow-up. The primary endpoint was a composite of mortality, first HF hospitalization, and improvement of quality of life at 6 months. Secondary endpoints included mortality, hospitalizations, and change in quality of life. Prospective Kaplan-Meier survival analyses were used for differences between FDC I/H and placebo groups and retrospective analyses were conducted within FDC I/H-treated and placebo groups. Results: Subgroup analysis for mortality, event-free survival (death or first HF hospitalization), and HF hospitalization showed that FDC I/H, compared with placebo, was effective with or without ACE inhibitors or β-blockers or other standard medications with all-point estimates favoring the FDC I/H group. Within the placebo-treated group, β-blockers or ACE inhibitors and/or ARBs were efficacious in improving survival (hazard ratio [HR] 0.33; p < 0.0001 for β-blocker use and HR 0.39; p = 0.01 for ACE inhibitor and/or ARB use). However, within the FDC I/H-treated group, use of β-blockers, but not ACE inhibitors and/or ARBs, provided additional significant benefit for survival (HR 0.44; p = 0.029 and HR 0.60; p = 0.34, respectively), event-free survival (HR 0.62; p = 0.034 and HR 0.72; p = 0.29, respectively) and the composite score of death, HF hospitalization and change in quality of life (p = 0.016 and p = 0.13, respectively). Conclusion: Based on the analysis of baseline medication use in the A-HeFT, FDC I/H was superior to placebo with or without β-blockers or ACE inhibitor. However, β-blockers but not ACE inhibitors and/or ARBs provided additional significant benefit in African-Americans with HF treated with FDC I/H. These analyses are hypotheses generating and their confirmation in clinical trials needs to be considered.

Original languageEnglish (US)
Pages (from-to)373-380
Number of pages8
JournalAmerican Journal of Cardiovascular Drugs
Volume7
Issue number5
DOIs
StatePublished - Jan 1 2007

Fingerprint

Angiotensin-Converting Enzyme Inhibitors
African Americans
Heart Failure
Angiotensin Receptor Antagonists
Placebos
Hospitalization
Mortality
Quality of Life
Disease-Free Survival
isosorbide-hydralazine combination
Systolic Heart Failure
Survival
Kaplan-Meier Estimate
Survival Analysis
Adrenergic Receptors
Therapeutics
Clinical Trials
Morbidity
Drug Therapy

Keywords

  • ACE inhibitors, therapeutic use
  • Angiotensin receptor antagonists, therapeutic use
  • Beta adrenergic receptor antagonists, therapeutic use
  • Heart failure, treatment
  • Hydralazine/isosorbide dinitrate, therapeutic use
  • Mortality
  • Quality of life

Cite this

Effects of ACE inhibitors or β-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American heart failure trial. / Ghali, Jalal K.; Tam, S. William; Ferdinand, Keith C.; Lindenfeld, Jo Ann; Sabolinski, Michael L.; Taylor, Anne L.; Worcel, Manuel; Curry, Charles L.; Cohn, Jay N.

In: American Journal of Cardiovascular Drugs, Vol. 7, No. 5, 01.01.2007, p. 373-380.

Research output: Contribution to journalArticle

Ghali, Jalal K. ; Tam, S. William ; Ferdinand, Keith C. ; Lindenfeld, Jo Ann ; Sabolinski, Michael L. ; Taylor, Anne L. ; Worcel, Manuel ; Curry, Charles L. ; Cohn, Jay N. / Effects of ACE inhibitors or β-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American heart failure trial. In: American Journal of Cardiovascular Drugs. 2007 ; Vol. 7, No. 5. pp. 373-380.
@article{b0c67dae4be04197a7656124889428ff,
title = "Effects of ACE inhibitors or β-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American heart failure trial",
abstract = "Background: In the A-HeFT (African-American Heart Failure Trial), treatment of African-American patients with New York Heart Association (NYHA) class III/IV heart failure (HF) with fixed-dose combination (FDC) of isosorbide dinitrate/hydralazine (I/H) reduced mortality and morbidity and improved patient reported functional status compared with standard therapy alone. Objective: To examine the benefit of FDC I/H in subgroups based on baseline drug therapy and to investigate whether ACE inhibitors and/or angiotensin receptor antagonists (angiotensin receptor blockers) [ARBs] or β-adrenoceptor antagonists (β-blockers) provided additional benefit in FDC I/H-treated African-American patients with HF. Study design: The A-HeFT was a double-blind, placebo-controlled study enrolling 1050 patients stabilized on optimal HF therapies and with NYHA class III/IV HF with systolic dysfunction conducted during the years 2001-4 with up to 18 months follow-up. The primary endpoint was a composite of mortality, first HF hospitalization, and improvement of quality of life at 6 months. Secondary endpoints included mortality, hospitalizations, and change in quality of life. Prospective Kaplan-Meier survival analyses were used for differences between FDC I/H and placebo groups and retrospective analyses were conducted within FDC I/H-treated and placebo groups. Results: Subgroup analysis for mortality, event-free survival (death or first HF hospitalization), and HF hospitalization showed that FDC I/H, compared with placebo, was effective with or without ACE inhibitors or β-blockers or other standard medications with all-point estimates favoring the FDC I/H group. Within the placebo-treated group, β-blockers or ACE inhibitors and/or ARBs were efficacious in improving survival (hazard ratio [HR] 0.33; p < 0.0001 for β-blocker use and HR 0.39; p = 0.01 for ACE inhibitor and/or ARB use). However, within the FDC I/H-treated group, use of β-blockers, but not ACE inhibitors and/or ARBs, provided additional significant benefit for survival (HR 0.44; p = 0.029 and HR 0.60; p = 0.34, respectively), event-free survival (HR 0.62; p = 0.034 and HR 0.72; p = 0.29, respectively) and the composite score of death, HF hospitalization and change in quality of life (p = 0.016 and p = 0.13, respectively). Conclusion: Based on the analysis of baseline medication use in the A-HeFT, FDC I/H was superior to placebo with or without β-blockers or ACE inhibitor. However, β-blockers but not ACE inhibitors and/or ARBs provided additional significant benefit in African-Americans with HF treated with FDC I/H. These analyses are hypotheses generating and their confirmation in clinical trials needs to be considered.",
keywords = "ACE inhibitors, therapeutic use, Angiotensin receptor antagonists, therapeutic use, Beta adrenergic receptor antagonists, therapeutic use, Heart failure, treatment, Hydralazine/isosorbide dinitrate, therapeutic use, Mortality, Quality of life",
author = "Ghali, {Jalal K.} and Tam, {S. William} and Ferdinand, {Keith C.} and Lindenfeld, {Jo Ann} and Sabolinski, {Michael L.} and Taylor, {Anne L.} and Manuel Worcel and Curry, {Charles L.} and Cohn, {Jay N.}",
year = "2007",
month = "1",
day = "1",
doi = "10.2165/00129784-200707050-00007",
language = "English (US)",
volume = "7",
pages = "373--380",
journal = "American Journal of Cardiovascular Drugs",
issn = "1175-3277",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - Effects of ACE inhibitors or β-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American heart failure trial

AU - Ghali, Jalal K.

AU - Tam, S. William

AU - Ferdinand, Keith C.

AU - Lindenfeld, Jo Ann

AU - Sabolinski, Michael L.

AU - Taylor, Anne L.

AU - Worcel, Manuel

AU - Curry, Charles L.

AU - Cohn, Jay N.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Background: In the A-HeFT (African-American Heart Failure Trial), treatment of African-American patients with New York Heart Association (NYHA) class III/IV heart failure (HF) with fixed-dose combination (FDC) of isosorbide dinitrate/hydralazine (I/H) reduced mortality and morbidity and improved patient reported functional status compared with standard therapy alone. Objective: To examine the benefit of FDC I/H in subgroups based on baseline drug therapy and to investigate whether ACE inhibitors and/or angiotensin receptor antagonists (angiotensin receptor blockers) [ARBs] or β-adrenoceptor antagonists (β-blockers) provided additional benefit in FDC I/H-treated African-American patients with HF. Study design: The A-HeFT was a double-blind, placebo-controlled study enrolling 1050 patients stabilized on optimal HF therapies and with NYHA class III/IV HF with systolic dysfunction conducted during the years 2001-4 with up to 18 months follow-up. The primary endpoint was a composite of mortality, first HF hospitalization, and improvement of quality of life at 6 months. Secondary endpoints included mortality, hospitalizations, and change in quality of life. Prospective Kaplan-Meier survival analyses were used for differences between FDC I/H and placebo groups and retrospective analyses were conducted within FDC I/H-treated and placebo groups. Results: Subgroup analysis for mortality, event-free survival (death or first HF hospitalization), and HF hospitalization showed that FDC I/H, compared with placebo, was effective with or without ACE inhibitors or β-blockers or other standard medications with all-point estimates favoring the FDC I/H group. Within the placebo-treated group, β-blockers or ACE inhibitors and/or ARBs were efficacious in improving survival (hazard ratio [HR] 0.33; p < 0.0001 for β-blocker use and HR 0.39; p = 0.01 for ACE inhibitor and/or ARB use). However, within the FDC I/H-treated group, use of β-blockers, but not ACE inhibitors and/or ARBs, provided additional significant benefit for survival (HR 0.44; p = 0.029 and HR 0.60; p = 0.34, respectively), event-free survival (HR 0.62; p = 0.034 and HR 0.72; p = 0.29, respectively) and the composite score of death, HF hospitalization and change in quality of life (p = 0.016 and p = 0.13, respectively). Conclusion: Based on the analysis of baseline medication use in the A-HeFT, FDC I/H was superior to placebo with or without β-blockers or ACE inhibitor. However, β-blockers but not ACE inhibitors and/or ARBs provided additional significant benefit in African-Americans with HF treated with FDC I/H. These analyses are hypotheses generating and their confirmation in clinical trials needs to be considered.

AB - Background: In the A-HeFT (African-American Heart Failure Trial), treatment of African-American patients with New York Heart Association (NYHA) class III/IV heart failure (HF) with fixed-dose combination (FDC) of isosorbide dinitrate/hydralazine (I/H) reduced mortality and morbidity and improved patient reported functional status compared with standard therapy alone. Objective: To examine the benefit of FDC I/H in subgroups based on baseline drug therapy and to investigate whether ACE inhibitors and/or angiotensin receptor antagonists (angiotensin receptor blockers) [ARBs] or β-adrenoceptor antagonists (β-blockers) provided additional benefit in FDC I/H-treated African-American patients with HF. Study design: The A-HeFT was a double-blind, placebo-controlled study enrolling 1050 patients stabilized on optimal HF therapies and with NYHA class III/IV HF with systolic dysfunction conducted during the years 2001-4 with up to 18 months follow-up. The primary endpoint was a composite of mortality, first HF hospitalization, and improvement of quality of life at 6 months. Secondary endpoints included mortality, hospitalizations, and change in quality of life. Prospective Kaplan-Meier survival analyses were used for differences between FDC I/H and placebo groups and retrospective analyses were conducted within FDC I/H-treated and placebo groups. Results: Subgroup analysis for mortality, event-free survival (death or first HF hospitalization), and HF hospitalization showed that FDC I/H, compared with placebo, was effective with or without ACE inhibitors or β-blockers or other standard medications with all-point estimates favoring the FDC I/H group. Within the placebo-treated group, β-blockers or ACE inhibitors and/or ARBs were efficacious in improving survival (hazard ratio [HR] 0.33; p < 0.0001 for β-blocker use and HR 0.39; p = 0.01 for ACE inhibitor and/or ARB use). However, within the FDC I/H-treated group, use of β-blockers, but not ACE inhibitors and/or ARBs, provided additional significant benefit for survival (HR 0.44; p = 0.029 and HR 0.60; p = 0.34, respectively), event-free survival (HR 0.62; p = 0.034 and HR 0.72; p = 0.29, respectively) and the composite score of death, HF hospitalization and change in quality of life (p = 0.016 and p = 0.13, respectively). Conclusion: Based on the analysis of baseline medication use in the A-HeFT, FDC I/H was superior to placebo with or without β-blockers or ACE inhibitor. However, β-blockers but not ACE inhibitors and/or ARBs provided additional significant benefit in African-Americans with HF treated with FDC I/H. These analyses are hypotheses generating and their confirmation in clinical trials needs to be considered.

KW - ACE inhibitors, therapeutic use

KW - Angiotensin receptor antagonists, therapeutic use

KW - Beta adrenergic receptor antagonists, therapeutic use

KW - Heart failure, treatment

KW - Hydralazine/isosorbide dinitrate, therapeutic use

KW - Mortality

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=35449008134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35449008134&partnerID=8YFLogxK

U2 - 10.2165/00129784-200707050-00007

DO - 10.2165/00129784-200707050-00007

M3 - Article

VL - 7

SP - 373

EP - 380

JO - American Journal of Cardiovascular Drugs

JF - American Journal of Cardiovascular Drugs

SN - 1175-3277

IS - 5

ER -